Contents

Search

rituximab/cyclophosphamide/doxorubicin/vincristine (Oncocin)/dexamethasone (R-CVAD)

Indications: - chemotherapy regimen for treatment of lymphomas - Burkitt's lymphoma - lymphoblastic lymphoma - acute lymphoblastic leukemia Dosage: - six 21-day cycles - rituximab (375 mg/m2) administered on day 1 of each cycle - on days 1-5 - cyclophosphamide (400 mg/m2) - doxorubicin (25 mg/m2) - vincristine (1 mg capped dose) - dexamethasone [1]

Related

rituximab/cyclophosphamide/doxorubicin/vincristine (Oncocin)/prednisone (R-CHOP)

General

antineoplastic combination (combination chemotherapy)

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015

Components

cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271] dexamethasone (Decadron, Maxidex, AK-Dex, Ozurdex) doxorubicin (Adriamycin, Rubex) rituximab (Rituxan, Mabthera, Truxima, Ruxience, Riabni) vincristine; 22-oxovincaleukoblastine; leurocristine (Oncovin, Vincasar PFS)